drugset / Trial / NCT01583647
A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the pharmacokinetics of laropiprant following administration of a single dose of 1 (Panel A) and 2 (Panel B) combination tablets of MK-0524A in adolescents with heterozygous familial hypercholesterolemia.
Timeline
- Start
- 2012-06
- Primary completion
- 2012-12
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Niacin | Small molecule | 1 g | Oral |
| Subject | Niacin | Small molecule | 2 g | Oral |
| Subject | laropiprant | Small molecule | 20 mg | Oral |
| Subject | laropiprant | Small molecule | 40 mg | Oral |